Journal of pediatric gastroenterology and nutrition
-
J. Pediatr. Gastroenterol. Nutr. · Nov 2007
Randomized Controlled Trial Multicenter StudySafety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease.
The primary objective was to assess the safety of esomeprazole 20 or 40 mg once daily in adolescents with clinically diagnosed gastroesophageal reflux disease (GERD). A secondary aim was to assess changes in GERD symptoms after esomeprazole therapy. ⋯ In adolescent patients with GERD, esomeprazole 20 or 40 mg daily for 8 weeks was well tolerated, and GERD-related symptoms were significantly reduced from baseline values in both groups.